Skip to content

The Effects of Hydration on Gut Health and Thinking

Investigating the Effects of Increased Water Consumption on Markers of Gut Health, Microbiota, and Executive Function

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05315531
Acronym
WatUP
Enrollment
23
Registered
2022-04-07
Start date
2021-08-23
Completion date
2022-07-29
Last updated
2024-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dehydration, Cognitive Change, Gastrointestinal Microbiota

Brief summary

The central hypothesis is that improving hydration through increased water consumption will change the relative abundance of mucolytic bacteria found in the stool. Therefore the specific aims are 1) to quantify intervention effects on fecal microbiota relative abundance and plasma lipopolysaccharide binding protein, 2) observe the effects of the intervention on bowel frequency and signs/symptoms of gastrointestinal stress, and 3) to investigate relations between executive function and hydration status.

Detailed description

A single arm 3-week hydration intervention will be employed where participants increase their water consumption to 2 (F) or 2.5(M) liters per day which is approximately 70% of the AI for daily water consumption. Pre-test and follow-up measures of fecal microbiota, urinary hydration status, cognitive function, circulating markers, and dietary intake will be assessed at baseline and at 3-week follow up via laboratory visits.

Interventions

DIETARY_SUPPLEMENTWater Intake

Participants will increase plain water consumption to at least 70% of the daily adequate intake for Americans depending on their sex.

Sponsors

Division of Nutritional Sciences, University of Illinois at Urbana-Champaign
CollaboratorUNKNOWN
University of Illinois at Urbana-Champaign
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

Single arm hydration water intake intervention with a baseline urine concentration threshold for eligibility

Eligibility

Sex/Gender
ALL
Age
19 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* 19-50 years of age * 18.5-34.49 kg/m2 * 24-hour UOsm above 500 mOsm/kg * No antibiotic use over the past 3 months * Absence of metabolic diseases and use of diuretics * Agree to maintain typical diet intake (e.g., dietary fiber) patterns during intervention * Avoid consuming prebiotic and probiotic supplements during study participation * Not pregnant * Agree to follow the study protocol

Exclusion criteria

* \<19 or \>50 years of age * \<18.5 or \>34.49 kg/m2 * 24-hour UOsm \<500 mOsm/kg * Antibiotic use over the past 3 months * Metabolic diseases and use of diuretics * Not agree to maintain typical diet intake (e.g., dietary fiber) patterns for the duration of the * intervention * Not agree with avoiding consuming prebiotic and probiotic supplements during study participation * Pregnant * Not agree to follow study protocol

Design outcomes

Primary

MeasureTime frameDescription
Fecal microbiota relative abundance3 weeks (baseline vs. follow-up)changes in the relative abundance of fecal microbiota
Plasma lipopolysaccharide (LPS)3 weeks (baseline vs. follow-up)changes in circulating LPS

Secondary

MeasureTime frameDescription
Attentional accuracy3 weeks (baseline vs. follow-up)Accuracy (%) on a computerized flanker task
Attentional Reaction Time3 weeks (baseline vs. follow-up)Reaction time (ms) on a computerized flanker task
Copeptin3 weeks (baseline vs. follow-up)changes in plasma copeptin concentration
24hr Urine Specific Gravity3 weeks (baseline vs. follow-up)changes in specific gravity (USG) of urine samples
Attentional processing speed3 weeks (baseline vs. follow-up)P3 event related potential latency (ms) using a computerized flanker task
24hr Urine Osmolality3 weeks (baseline vs. follow-up)changes in osmolality (mOsmol/kg) of urine samples

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026